ZA201403396B - Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions - Google Patents

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Info

Publication number
ZA201403396B
ZA201403396B ZA2014/03396A ZA201403396A ZA201403396B ZA 201403396 B ZA201403396 B ZA 201403396B ZA 2014/03396 A ZA2014/03396 A ZA 2014/03396A ZA 201403396 A ZA201403396 A ZA 201403396A ZA 201403396 B ZA201403396 B ZA 201403396B
Authority
ZA
South Africa
Prior art keywords
imidazol
ylmethyl
tetrahydro
quinoline
conditions
Prior art date
Application number
ZA2014/03396A
Other languages
English (en)
Inventor
Mohammed I Dibas
Edward C Hsia
John E Donello
Daniel W Gil
Original Assignee
Allegran Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201403396(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allegran Inc filed Critical Allegran Inc
Publication of ZA201403396B publication Critical patent/ZA201403396B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
ZA2014/03396A 2011-11-10 2014-05-12 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions ZA201403396B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558104P 2011-11-10 2011-11-10
PCT/US2012/064075 WO2013070861A1 (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Publications (1)

Publication Number Publication Date
ZA201403396B true ZA201403396B (en) 2015-07-29

Family

ID=47178364

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/03396A ZA201403396B (en) 2011-11-10 2014-05-12 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Country Status (22)

Country Link
US (4) US20130123303A1 (enExample)
EP (3) EP2776034B1 (enExample)
JP (2) JP6359456B2 (enExample)
KR (1) KR102004563B1 (enExample)
CN (1) CN104136029A (enExample)
AR (1) AR088845A1 (enExample)
AU (2) AU2012335803B2 (enExample)
BR (1) BR112014011336A2 (enExample)
CA (1) CA2855005C (enExample)
CL (1) CL2014001242A1 (enExample)
DK (1) DK2776034T3 (enExample)
ES (1) ES2635421T3 (enExample)
IL (3) IL232483B (enExample)
MX (1) MX350662B (enExample)
MY (1) MY182553A (enExample)
PH (1) PH12014501051A1 (enExample)
RU (2) RU2630978C2 (enExample)
SG (3) SG11201402246RA (enExample)
TW (3) TW202014189A (enExample)
UA (1) UA109359C2 (enExample)
WO (1) WO2013070861A1 (enExample)
ZA (1) ZA201403396B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
AU2014262960A1 (en) * 2013-05-06 2015-11-26 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
FR3061434B1 (fr) * 2017-01-04 2019-07-12 Pierre Fabre Dermo-Cosmetique Composition cosmetique comprenant une association d'huile de pongamia et de pentylene glycol 4-t-butylcyclohexanol pour lutter contre la rosacee
RU2727695C1 (ru) * 2020-02-13 2020-07-22 Мурад Умарович Магомедов Способ комплексного лечения ринофимы

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE319456T1 (de) * 1998-05-08 2006-03-15 Univ Miami Verwendung von tetracyclinen zur behandlung von störungen der meibomschen drüsen
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
ZA200604403B (en) * 2003-11-20 2007-09-26 Othera Pharmaceuticals Inc Amelioration of macular degeneration and other ophthalmic diseases
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
CA2567401C (en) * 2004-05-25 2013-11-12 Sansrosa Pharmaceutical Development, Inc. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
US7323477B2 (en) * 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
RU2321399C1 (ru) * 2006-06-01 2008-04-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" Способ лечения больных розацеа
WO2008124151A2 (en) * 2007-04-09 2008-10-16 Avicena Group, Inc. Use of creatine compounds for the treatment of eye disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
CA2732521C (en) * 2008-08-01 2017-11-07 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
EP2493309A4 (en) * 2009-10-26 2013-05-01 Galderma Pharma Sa METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
RU2535008C2 (ru) * 2010-03-26 2014-12-10 Галдерма Ресерч Энд Девелопмент Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии
MX2012010824A (es) * 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema.
US20130190317A1 (en) * 2010-08-06 2013-07-25 Galderma Research & Development Snc Combination of compounds for treating or preventing skin diseases

Also Published As

Publication number Publication date
AU2012335803A1 (en) 2014-05-29
AU2016216627A1 (en) 2016-09-08
KR20140107237A (ko) 2014-09-04
TW201713338A (zh) 2017-04-16
NZ624771A (en) 2016-11-25
EP3763370A1 (en) 2021-01-13
JP2017149767A (ja) 2017-08-31
SG11201402246RA (en) 2014-06-27
JP6359456B2 (ja) 2018-07-18
SG10201609145PA (en) 2016-12-29
US9308201B2 (en) 2016-04-12
PH12014501051A1 (en) 2022-11-02
TWI708604B (zh) 2020-11-01
RU2667645C1 (ru) 2018-09-21
TWI580424B (zh) 2017-05-01
IL261269A (en) 2018-10-31
EP3184110B1 (en) 2020-10-07
CA2855005A1 (en) 2013-05-16
MX350662B (es) 2017-09-13
CL2014001242A1 (es) 2014-11-14
JP2014533271A (ja) 2014-12-11
SG10201809506TA (en) 2018-11-29
EP3184110A1 (en) 2017-06-28
MY182553A (en) 2021-01-25
EP2776034B1 (en) 2017-03-22
RU2014122758A (ru) 2015-12-20
MX2014005640A (es) 2014-09-22
KR102004563B1 (ko) 2019-07-26
US20150231128A1 (en) 2015-08-20
CA2855005C (en) 2016-11-22
AU2012335803B2 (en) 2016-05-26
AR088845A1 (es) 2014-07-10
EP2776034A1 (en) 2014-09-17
RU2630978C2 (ru) 2017-09-15
JP6526737B2 (ja) 2019-06-05
TW202014189A (zh) 2020-04-16
US20130123303A1 (en) 2013-05-16
WO2013070861A1 (en) 2013-05-16
UA109359C2 (xx) 2015-08-10
IL268757A (en) 2019-10-31
ES2635421T3 (es) 2017-10-03
CN104136029A (zh) 2014-11-05
DK2776034T3 (en) 2017-07-10
TW201328694A (zh) 2013-07-16
IL232483A0 (en) 2014-06-30
IL232483B (en) 2018-10-31
US20170095466A1 (en) 2017-04-06
BR112014011336A2 (pt) 2017-05-02
AU2016216627B2 (en) 2017-10-19
US20160051534A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
LT2925757T (lt) Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
PL2643004T3 (pl) Kompozycja oligosacharydów do leczenia chorób skóry
PH12013501333A1 (en) Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
HUE041553T2 (hu) Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
MX349004B (es) Nuevos compuestos.
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
DK3292875T3 (en) Compositions and methods for treating diseases
IL222890A0 (en) Medicaments for the treatment of il-1beta related conditions
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
HUE037611T2 (hu) AMP-származékok szívbetegségek kezelésére
IL268757A (en) Pharmaceutical preparations containing 7-(H1-imidazol-4-ylmethyl)-8,7,6,5-tetrahydroquinoline for the treatment of skin diseases and conditions
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
ZA201409073B (en) Compositions and methods for treating or preventing pneumovirus infection and associated diseases
IL225755A0 (en) Amido-6 derivatives of epoxymorphinans-a5, 4 for the treatment of pain
PL392436A1 (pl) Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
EP2578206A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISORDERS OF THE LOWER PART OF THE UROGENITAL SYSTEM
EP2526947A4 (en) USE OF AT LEAST ONE ISOQUINOLINIC COMPOUND OF FORMULA (I), PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASES, AND METHOD OF TREATING OR PREVENTING NEURODEGENERATIVE DISEASES
PT2456445E (pt) Agente para o tratamento de condições da pele
ZA201304121B (en) Arlysulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders
GB201018325D0 (en) Treatment for dupuytren's disease
HK1188955A (en) Methods for treating diseases of the retina